Kyowa Kirin and Hisamitsu link up for sublingual fentanyl
This article was originally published in Scrip
Kyowa Hakko Kirin and Hisamitsu have entered into an agreement for the joint distribution and promotion of a sublingual formulation of fentanyl citrate in Japan for the treatment of breakthrough pain in cancer patients.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.